The following was first published on Sharyl Attkisson‘s Substack. Medicine saves lives every day, combating everything from infections to chronic pain. But the little-discussed reality is that adverse drug reactions are the third leading cause of death in the US, […]
Rampant conflicts of interest in medicine among those who decide ‘what’s good for us’ The following article was first published on Sharyl Attkisson‘s FREE Substack. We shouldn’t have been surprised that the Covid experience was so marred by financial conflicts
An exclusive analysis of 52 disease trends and toxins The following article was first published on SHARYL ATTKISSON‘s free Substack A tidal wave of health conditions is crashing over us, growing more common with each passing year. From autism to
A new study finds a concerning increase in risk of blindness with popular semaglutides This article was first published in SHARYL ATTKISSON‘s free Substack A new study finds a concerning increase in risk of blindness with weekly use of popular
Blindness Risk from Ozempic and Wegovy Mirrors that of Viagra Read More »
The following information is from Children’s Health Defense. A new study has linked the diabetes and weight-loss drug Ozempic to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition that causes sudden vision loss due to reduced blood
(STUDY) Ozempic linked to blindness as Novo Nordisk downplays risks Read More »
An update to our reporting on two recently-approved Alzheimer’s drugs: aducanumab and Lecanemab. FDA advisers and many independent watchdogs said there’s no good evidence the hugely expensive shots make a meaningful difference, and they could cause serious side effects. But
A physician is suing the FDA for its lack of action to inform consumers taking selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) about potential long-term side-effects. These drugs are widely-used antidepressants. A citizen petition requests that the FDA
(READ) FDA sued for inaction on warnings about antidepressants’ sexual side effects Read More »
The following is a news analysis. The vast majority of drugs – more than 90 per cent – only work in 30 or 50 per cent of the people. Dr. Allen Roses, worldwide vice president of genetics at GlaxoSmithKline (2003)
Pharma exec say most drugs don’t work on most people Read More »
